Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Citagenix Sale Announced this AM

<< Previous

Bullboard Posts

Next >>

Comment by Scotchnoiceon May 03, 2022 8:31am

135 Views

Post# 34650415

RE:RE:RE:Citagenix Sale Announced this AM

Ok thanks that was my ussumption but I wasn't 100% sure.

As far as I know the value of CGX when ATE acquired it, in october 2015, was 4,95 m$, the cumulated loss of CGX between then and now is close to 10m$.

The guaranteed payment by Hansamed is only 3,5m$ the rest is linked to milestones... and those 3,5m$ will be devided into 4 equal payments over 3 years!

And I would be surprised if CGX activities remain in Laval since Hansa does exactly the same thing.

That's a pretty bad job ATE has done with CGX or what?....

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale